Health Canada has released a draft revised Quality of natural health products guide (Version 4.0) for consultation, marking the first revision to the guide since Version 3.1 was published in May 2015. The consultation opened July 20, 2026, and Health Canada says the revision is intended to reflect current science, provide additional guidance and make the document clearer and easier to use. The consultation closes September 20, 2026, with a final version and subsequent transition period anticipated later this year.
The purpose of this guide is to help industry members who are creating and maintaining finished product specifications for product licenses or product manufacturing, or arranging real-time or stability testing studies. For regulatory affairs professionals, the revision is significant because it provides considerably more detail on how companies should establish, maintain and update finished product specifications (FPS) and demonstrate quality throughout an NHP’s lifecycle.
A more structured, science-based approach to specifications
The draft places greater emphasis on establishing specifications using current scientific standards and internationally recognized references. Health Canada states that FPS should contain appropriate tests, methods, target quantities and acceptance criteria, while allowing certain attributes to be controlled through development or in-process testing where supported by a scientific rationale and relevant data. This risk-based flexibility can help companies avoid unnecessary finished-product testing while maintaining appropriate controls.
The guide also reinforces the expectation that specifications should reflect the most current versions of applicable pharmacopoeial standards. Companies relying on pharmacopoeial references will therefore need processes to monitor relevant updates and assess their impact on existing specifications.
Greater specificity for identity, quantity and potency
The revised guide provides detailed expectations for demonstrating medicinal-ingredient identity, including more explicit direction for botanicals, extracts, isolates, vitamins, minerals, enzymes, proteins, essential fatty acids and probiotics. For probiotics in particular, Health Canada calls for unambiguous strain identification using current methodology, including phenotypic and genotypic characterization and whole-genome sequencing approaches where appropriate.
Expanded performance and dosage-form expectations
Performance testing is more clearly integrated into the quality framework than compared to previous guidance documents. For instance, the guidance specifically addresses gummies, noting that disintegration testing remains relevant because the dosage form’s matrix can affect medicinal-ingredient release. It’s important that any Natural Health Products taken orally have dissolution or disintegration testing arranged whenever appropriate as it ensures the medicinal ingredients are released when the product is taken.
More comprehensive purity and impurity controls
One of the most consequential areas of the revision is purity. The draft provides detailed expectations for physical, chemical and microbial contaminants, as well as elemental impurities, pesticides, mycotoxins, adulterants, allergens and process-related impurities. It also introduces product-specific considerations for areas such as animal-derived materials, marine oils, probiotics and oxidative stability.
Importantly, companies are expected to consider evolving impurity risks. For example, the guide addresses nitrosamines, packaging-related extractables and leachables, and changes in impurity profiles resulting from new raw-material sources or manufacturing processes. Such changes may trigger specification updates and, where applicable, product licence amendments.
Stronger focus on stability and in-use performance
The revised guidance expands expectations around stability, including the influence of packaging, storage conditions, manufacturing changes and product-specific characteristics. A notable addition is explicit guidance on in-use stability for multiple-dose products. Where an in-use period is claimed, stability studies should simulate consumer use, including repeated opening, sampling and closure throughout the product’s shelf life.
What should companies do now?
Although the document remains a draft for consultation, the proposed changes provide a useful roadmap for regulatory and quality teams. Companies should consider conducting a gap assessment of existing FPS, analytical methods, impurity controls, stability programs and supporting documentation against the draft Version 4.0.
The practical takeaway is clear: Health Canada’s revised Quality Guide moves NHP quality expectations toward greater scientific specificity, stronger lifecycle oversight and closer alignment with contemporary international standards—while retaining flexibility where alternative approaches are scientifically justified.
Blog Author
Matthew Lai
Matthew holds a B.Sc. in Honours Biology from the University of Waterloo and a Certificate in Regulatory Affairs from Humber College, where he developed a strong interest in Quality Assurance and the regulatory standards for medical devices, drugs, and natural health products. With nearly 4 years of experience, Matthew has been working closely with clients interested in manufacturing or importing Natural Health Products.
